Junki Takenaka

Dr. Junki Takenaka

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
ZLZongyao Li
Zongyao Li
KKKazuhiro Kitajima
Kazuhiro Kitajima
KHKenji Hirata
Kenji Hirata
RTRen Togo
Ren Togo
JTJunki Takenaka
Junki Takenaka
MHMiki Haseyama
Miki Haseyama
Background: To improve the diagnostic accuracy of axillary lymph node (LN) metastasis in breast cancer patients using 2-[18F]FDG-PET/CT, we constructed an artificial intelligence (AI)-assisted diagnosis system that uses deep-learning technologies. Materials and methods: Two clinicians and the new AI system retrospectively analyzed and diagnosed 414 axillae of 407 patients with biopsy-proven breast cancer who had undergone 2-[18F]FDG-PET/CT before a mastectomy or breast-conserving surgery with a sentinel lymph node (LN) biopsy and/or axillary LN dissection. We designed and trained a deep 3D convolutional neural network (CNN) as the AI model. The diagnoses from the clinicians were blended with the diagnoses from the AI model to improve the diagnostic accuracy. Results: Although the AI model did not outperform the clinicians, the diagnostic accuracies of the clinicians were considerably improved by collaborating with the AI model: the two clinicians' sensitivities of 59.8% and 57.4% increased to 68.6% and 64.2%, respectively, whereas the clinicians' specificities of 99.0% and 99.5% remained unchanged. Conclusions: It is expected that AI using deep-learning technologies will be useful in diagnosing axillary LN metastasis using 2-[18F]FDG-PET/CT. Even if the diagnostic performance of AI is not better than that of clinicians, taking AI diagnoses into consideration may positively impact the overall diagnostic accuracy.

27 October 2022 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JTJunki Takenaka
Junki Takenaka
SWShiro Watanabe
Shiro Watanabe
TATakashige Abe
Takashige Abe
KHKenji Hirata
Kenji Hirata
YUYuko Uchiyama
Yuko Uchiyama
KKKohsuke Kudo
Kohsuke Kudo

24 April 2024 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
NWNaoto Wakabayashi
Naoto Wakabayashi
SWShiro Watanabe
Shiro Watanabe
TATakashige Abe
Takashige Abe
JTJunki Takenaka
Junki Takenaka
KHKenji Hirata
Kenji Hirata
KKKohsuke Kudo
Kohsuke Kudo

13 September 2023 in Neuroendocrinology
Verified
Journal Article
Open access
PDF file
JTJunki Takenaka
Junki Takenaka
SWShiro Watanabe
Shiro Watanabe
TATakashige Abe
Takashige Abe
TTTakahiro Tsuchikawa
Takahiro Tsuchikawa
STSatoshi Takeuchi
Satoshi Takeuchi
KKKohsuke Kudo
Kohsuke Kudo
Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours that produce catecholamines. [131I] metaiodobenzylguanidine (MIBG)-avid unresectable or metastatic PPGLs are treated with [131I] MIBG radionuclide therapy. A high metabolic tumour volume (MTV) and total lesion glycolysis (TLG) can be poor prognostic factors. Therefore, we evaluated the metabolic responses to [131I] MIBG therapy with respect to other clinical factors. Methods: A retrospective study was performed on a series of 20 patients who underwent FDG-PET before and after [131I] MIBG therapy. We administered a single dose comprising 5.5 GBq of [131I] MIBG (usually three times; for some cases, the number was increased or decreased considering treatment efficacy and side effects). Semi-quantitative parameters (SUVmax, MTV, and TLG) were calculated using the liver SUV (mean + 3 × standard deviation) as a threshold on Metavol software. The semi-quantitative FDG-PET parameters for determining response were complete response (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). We divided our study participants into the PD and non-PD groups (i.e., SD + PR + CR) and compared the overall survival (OS) between the two groups. Subsequently, we evaluated the relationships between metabolic response and age, sex, tumour type, metastatic site, chemotherapy or external radiation history, and 24-h urine catecholamine levels by univariate logistic regression analyses. Results: Both MTV-based and TLG-based criteria for PD versus non-PD were significant prognostic factors (p = 0.014). However, treatment response as evaluated based on the SUVmax was not a significant predictor. Higher urinary dopamine levels were associated with poor metabolic response as assessed by MTV and TLG (OR 1.002, p = 0.029). The other clinical parameters were non-significant. Conclusion: Poor metabolic response (measured with MTV and TLG) to [131I] MIBG therapy in unresectable or metastatic PPGLs was related to shorter OS. The poor metabolic response can be predicted using the urinary dopamine level.

9 November 2023 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
SWShiro Watanabe
Shiro Watanabe
KHKenji Hirata
Kenji Hirata
KMKeiichi Magota
Keiichi Magota
JTJunki Takenaka
Junki Takenaka
NWNaoto Wakabayashi
Naoto Wakabayashi
KKKohsuke Kudo
Kohsuke Kudo

16 August 2022 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
SWShiro Watanabe
Shiro Watanabe
SOShozo Okamoto
Shozo Okamoto
KAKazumasa Akikawa
Kazumasa Akikawa
NMNoriyuki Miyamoto
Noriyuki Miyamoto
MOMiyuki Okamura-Kawasaki
Miyuki Okamura-Kawasaki
KKKohsuke Kudo
Kohsuke Kudo